Phase 3 EMERALD Trial: Elacestrant
Along with the Oncology Brothers, Paoloa Tarantino, MD, discusses how the Phase 3 EMERALD trial of elacestrant in ER+/HER2–- metastatic breast cancer highlights the importance of ESR1 mutation testing, endocrine sensitivity, and personalized treatment strategies for optimizing patient outcomes.
EP. 1: Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBC
November 22nd 2024Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- metastatic breast cancer, particularly in patients with ESR1 mutations.
Watch
EP. 2: Incidence of ESR1 mutations and best practices for testing
November 22nd 2024Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations (ESR1m) are commonly observed in HR+ breast cancer, particularly after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1m mutations at both the initial diagnosis of metastatic breast cancer (MBC) and at each subsequent progression using liquid biopsy assays.
Watch
